e-learning
resources
London 2016
Monday, 05.09.2016
New findings in mucosal immunology
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Over expression of endothelin-1 (ET-1) in lung fibroblasts (LFb) from patients with pulmonary arterial hypertension (PAH), evidence for loss of inhibitory control
Kurt Racke (Bonn, Germany), Kurt Racke, Margarita Fuhrmann, Uwe R. Juergens, Soni Pulamsetti, Werner Seeger
Source:
International Congress 2016 – New findings in mucosal immunology
Session:
New findings in mucosal immunology
Session type:
Poster Discussion
Number:
1820
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Kurt Racke (Bonn, Germany), Kurt Racke, Margarita Fuhrmann, Uwe R. Juergens, Soni Pulamsetti, Werner Seeger. Over expression of endothelin-1 (ET-1) in lung fibroblasts (LFb) from patients with pulmonary arterial hypertension (PAH), evidence for loss of inhibitory control. Eur Respir J 2016; 48: Suppl. 60, 1820
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Definition and history of sarcoidosis
The definition of pulmonary hypertension: history, practical implications and current controversies
Related content which might interest you:
Pulmonary arterial hypertension (PAH) in mice lacking the vasoactive intestinal polypeptide (VIP) gene: morphometric evidence for vascular remodeling
Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals
Year: 2006
Role of tadalafil in patients with hypoxia / lung disease induced (group 3) pulmonary hypertension
Source: International Congress 2016 – Pulmonary hypertension: the clinic I
Year: 2016
Expression of fetal genes in pulmonary arterial hypertension
Source: Annual Congress 2005 - Pulmonary hypertension and fibrosis: novel mechanisms
Year: 2005
Microarray analysis of pulmonary gene expression in mice lacking the vasoactive intestinal peptide (VIP) gene: confirmation of a role in asthma and pulmonary arterial hypertension (PAH)
Source: Annual Congress 2006 - Cellular mechanisms of airway disease
Year: 2006
Pulmonary arterial hypertension (PAH) in patients with lung sarcoidosis (LS)
Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis
Year: 2008
The transcription factor slug is increased in pulmonary artery endothelial cells of COPD patients
Source: Annual Congress 2013 –Pulmonary circulation: basic science
Year: 2013
Human apyrase (APT102) treatment attenuates the development of severe pulmonary arterial hypertension (PAH)
Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments
Year: 2013
Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension
Source: International Congress 2016 – Clinic of pulmonary hypertension
Year: 2016
Arterial hypertension (AH) and endothelial function (EF) in patients with COPD
Source: Annual Congress 2011 - COPD mechanisms
Year: 2011
Tyrosine kinase inhibition in pulmonary hypertension: the anti-proliferative approach
Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals
Year: 2006
Serotonin transporter genes, pulmonary haemodynamics and pulmonary hypertension
Source: Annual Congress 2005 - Scientific year in review
Year: 2005
A possible role of plasma serotonin (5-HT) and histamin level in pulmonary hypertension (PH) in patients with interstitial lung diseases (ILD)
Source: Eur Respir J 2001; 18: Suppl. 33, 416s
Year: 2001
PSGR olfactory receptor: A new potential target in pulmonary arterial hypertension
Source: International Congress 2016 – Pulmonary hypertension and pulmonary embolism: from the bench to the bedside
Year: 2016
Bosentan treatment in pulmonary arterial hypertension (PAH) associated with interstitial lung diseases (ILDs)
Source: Eur Respir J 2006; 28: Suppl. 50, 426s
Year: 2006
Inhibition of the Rho-kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation
Source: Annual Congress 2006 - Pulmonary circulation: inflammation and remodelling
Year: 2006
Endothelial-derived MIF contributes to pulmonary endothelial cell proliferation in human pulmonary arterial hypertension
Source: International Congress 2015 – Pulmonary hypertension: promising small molecules
Year: 2015
Role of anti-proliferative therapy in PAH
Source: Research Seminar 2008 - The Pulmonary Circulation: Scleroderma-Related Pulmonary Arterial Hypertension
Year: 2008
Pulmonary artery pressure (PAP) reduction by systemic and inhaled nitroglycerin (NTG) in an isolated rabbit lung model of pulmonary hypertension (PH)
Source: Eur Respir J 2003; 22: Suppl. 45, 270s
Year: 2003
MIF/CD74 contributes to the endothelial pro-inflammatory phenotype in pulmonary arterial hypertension
Source: Annual Congress 2013 –Pulmonary circulation: basic science
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept